CA2896979C - Methods for purification of arylsulfatase a - Google Patents

Methods for purification of arylsulfatase a Download PDF

Info

Publication number
CA2896979C
CA2896979C CA2896979A CA2896979A CA2896979C CA 2896979 C CA2896979 C CA 2896979C CA 2896979 A CA2896979 A CA 2896979A CA 2896979 A CA2896979 A CA 2896979A CA 2896979 C CA2896979 C CA 2896979C
Authority
CA
Canada
Prior art keywords
chromatography
protein
asa
column
ultrafiltration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2896979A
Other languages
English (en)
French (fr)
Other versions
CA2896979A1 (en
Inventor
Dave Nichols
Igor Quinones-Garcia
Bee Lin CHEANG
Mei Huei JANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA2896979A1 publication Critical patent/CA2896979A1/en
Application granted granted Critical
Publication of CA2896979C publication Critical patent/CA2896979C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Sustainable Development (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2896979A 2013-01-09 2014-01-09 Methods for purification of arylsulfatase a Active CA2896979C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750693P 2013-01-09 2013-01-09
US61/750,693 2013-01-09
PCT/US2014/010856 WO2014110246A1 (en) 2013-01-09 2014-01-09 Methods for purification of arylsulfatase a

Publications (2)

Publication Number Publication Date
CA2896979A1 CA2896979A1 (en) 2014-07-17
CA2896979C true CA2896979C (en) 2023-05-02

Family

ID=50002885

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2896979A Active CA2896979C (en) 2013-01-09 2014-01-09 Methods for purification of arylsulfatase a

Country Status (12)

Country Link
US (3) US11407984B2 (https=)
EP (1) EP2943568B1 (https=)
JP (5) JP6427502B2 (https=)
CN (4) CN104903442A (https=)
AU (3) AU2014205441B2 (https=)
BR (1) BR112015015948B1 (https=)
CA (1) CA2896979C (https=)
EA (1) EA030551B1 (https=)
ES (1) ES2768261T3 (https=)
HK (1) HK1214622A1 (https=)
MX (2) MX372711B (https=)
WO (1) WO2014110246A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2625511T3 (es) * 2011-07-08 2017-07-19 Shire Human Genetic Therapies, Inc. Métodos para la purificación de arylsulfatasa A
AU2014205441B2 (en) 2013-01-09 2019-12-12 Takeda Pharmaceutical Company Limited Methods for purification of arylsulfatase A
EP3236772A4 (en) * 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
EP3337819B1 (en) * 2015-08-20 2024-02-21 F. Hoffmann-La Roche AG Method of purifying for producing recombinant polypeptides using fkpa
CA3015685A1 (en) * 2016-03-16 2017-09-21 Phoenix Tissue Repair, Inc. Methods of purifying collagen 7
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
WO2019126376A1 (en) * 2017-12-19 2019-06-27 Shire Human Genetic Therapies, Inc. Purified arylsulfatase a and compositons thereof
KR20250016468A (ko) * 2018-02-02 2025-02-03 엔지반트 테라퓨틱스 게엠베하 파버병을 치료하는 방법
KR102791798B1 (ko) * 2018-04-12 2025-04-07 암젠 인크 안정한 단백질 조성물의 제조 방법
CN112082832B (zh) * 2019-06-12 2022-03-29 华南理工大学 一种保存城市污水中硫酸酯结合体和葡萄糖苷醛酸结合体的方法
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110632052A (zh) * 2019-10-25 2019-12-31 山西师范大学 土壤芳基硫酸酯酶活性的荧光光谱检测法
CN115066266A (zh) * 2019-12-12 2022-09-16 伊莱利利公司 用环保洗涤剂灭活病毒的方法
CN112759643B (zh) * 2021-03-17 2023-05-30 华兰生物工程股份有限公司 一种血清白蛋白的脱脂方法
CN116693659B (zh) * 2023-07-11 2025-03-28 浙江大学 一种分离重组人血白蛋白的两步混合模式层析方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314997A (en) 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4315919A (en) 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
CA2041280A1 (en) * 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
AU750143B2 (en) 1998-01-27 2002-07-11 Zymenex A/S Method for treating acute intermittent porphyria (AIP) and other porphyric diseases
DK2270044T3 (en) 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
NZ509135A (en) 1998-06-09 2002-10-25 Statens Seruminstitut A third generation intravenous immunoglobulin G (IVIG) purified using column chromatographic ion exchange methods
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
WO2001007065A2 (en) 1999-07-27 2001-02-01 Hemebiotech A/S PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2429210A1 (en) 2000-11-15 2002-05-23 Jason C. Goodrick Expression system for recombinant proteins
AU2002317700A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
AU2002317701A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
EP1402014A1 (en) 2001-06-29 2004-03-31 Hemebiotech A/S A process for purification of recombinant porphobilinogen deaminase
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
AU2003222568B2 (en) 2002-01-11 2009-05-07 Bioasis Technologies, Inc. Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
WO2003066669A2 (en) 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US8536315B2 (en) * 2004-01-30 2013-09-17 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulftase
SI1740204T1 (en) 2004-04-01 2018-07-31 Chiesi Farmaceutici S.P.A. MEDICAL APPLICATION OF ALFA-MANOSIDES
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
ES2928096T3 (es) 2006-04-04 2022-11-15 Takeda Pharmaceuticals Co Un proceso para la concentración de un polipéptido
BRPI0919879A2 (pt) * 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
NZ605873A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of arylsulfatase a
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
AU2014205441B2 (en) 2013-01-09 2019-12-12 Takeda Pharmaceutical Company Limited Methods for purification of arylsulfatase A

Also Published As

Publication number Publication date
AU2022221475B2 (en) 2025-05-22
US11407984B2 (en) 2022-08-09
JP2016504040A (ja) 2016-02-12
JP2018171067A (ja) 2018-11-08
HK1216429A1 (en) 2016-11-11
CN104903442A (zh) 2015-09-09
MX372711B (es) 2020-04-21
JP2024001160A (ja) 2024-01-09
BR112015015948A2 (https=) 2017-08-15
AU2020201079A1 (en) 2020-03-05
HK1214622A1 (zh) 2016-07-29
EP2943568B1 (en) 2019-11-20
MX2015008875A (es) 2015-10-22
WO2014110246A1 (en) 2014-07-17
EA030551B1 (ru) 2018-08-31
US20230235303A1 (en) 2023-07-27
AU2022221475A1 (en) 2022-09-22
JP7663649B2 (ja) 2025-04-16
CN120665836A (zh) 2025-09-19
US12319940B2 (en) 2025-06-03
CN112126634A (zh) 2020-12-25
BR112015015948B1 (pt) 2022-05-17
AU2014205441A1 (en) 2015-06-25
EP2943568A1 (en) 2015-11-18
JP2020015750A (ja) 2020-01-30
AU2020201079B2 (en) 2022-05-26
EA201590826A1 (ru) 2015-11-30
JP7407161B2 (ja) 2023-12-28
JP2022023225A (ja) 2022-02-07
US11884945B2 (en) 2024-01-30
JP6427502B2 (ja) 2018-11-21
CN119979504A (zh) 2025-05-13
US20150353904A1 (en) 2015-12-10
US20240392268A1 (en) 2024-11-28
AU2014205441B2 (en) 2019-12-12
CA2896979A1 (en) 2014-07-17
ES2768261T3 (es) 2020-06-22
MX2020003798A (es) 2020-08-03

Similar Documents

Publication Publication Date Title
AU2022221475B2 (en) Methods for purification of arylsulfatase a
AU2018200230B2 (en) Purification of iduronate-2-sulfatase
HK1216429B (en) Methods for purification of arylsulfatase a
WO2024176112A1 (en) Large scale production of recombinant arylsulfatase a and compositions thereof
AU2018393045A1 (en) Purified arylsulfatase A and compositons thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181221

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241224